Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 Response-Guided Neoadjuvant Therapy in Stage II-III HER2-positive Breast Cancer
NCT07787338Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Sep 2026
- Primary completion
- Apr 2029
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab rezetecan in HER2-positive breast cancer, sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT07787338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07787338.